The Biomarker: Melanoma
Sanjiv S. Agarwala, MD
Video Categories: The Biomarker
PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.
Dr Susan K. Boolbol talks about the importance of objective evidence provided by the Breast Cancer IndexSM (BCI) in treatment decision making.
Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.